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Missense and truncating mutation in APTX gene are respon-
sible of ataxia with oculomotor apraxia type 1 (AOA1) an
autosomal recessive disorder characterized by early onset,
progressive ataxia, peripheral neuropathy, oculomotor
apraxia, and cerebellar atrophy.1,2 We have already reported
two patients with onset at 25 and 29 years suggesting that
AOA1 should be considered in patients with onset after 25
years.3 Here, we report a patient with a very late onset and a
new mutation further expanding the clinical and molecular
spectrum of the disease.
The coding sequence of APTX was analyzed using dena-
turing high-performance liquid chromatography in 15 index
cases selected among 90 sporadic late-onset non–Friedreich
ataxia (FRDA) patients. The inclusion criteria were onset be-
tween 25 and 50 years, sporadic occurrence, and clinical
and/or neurophysiological signs of peripheral neuropathy.
APTX analysis showed a new homozygous 6668T3C mu-
tation (exon 5) in one patient, resulting in the substitution
of proline for leucine at codon 223 (L223P). Onset of the
disease was at age 40 years with ataxia followed by dysarthria.
Neurological examination showed mild gait and limb ataxia,
slurred speech, dysphagia, normal ocular movements, tongue
and limb fasciculations, brisk jaw jerk, areflexia, and de-
creased vibration sense at the external malleoli. Normal se-
rum creatine kinase and albumin, mild familial hypercholes-
terolemia, and hypertrigliceridemia were observed.
Motor (47m/sec in the elbow-wrist segment; lower limit
54) and sensory (43.3 m/sec in the digit III–wrist segment;
lower limit 51) conduction velocities were slightly decreased at
the median nerve, and sensory action potential was markedly
reduced at wrist (1.8 V; lower limit 6). Electromyogram
showed a neurogenic pattern in the anterior tibial muscle.
Brain magnetic resonance imaging showed cerebellar atrophy.
After 20 years of disease, the patient walks without supports
and is still working, and only speech is significantly worsened.
These findings suggest that the new mutation is associated
with a peculiarly mild phenotype. Homology modeling calcu-
lations performed for aprataxin and its L223P mutant showed
that H166-F282 sequence is compatible with a HIT-like do-
main for both proteins (Fig). However, the P223L substitu-
tion falls in the middle of an -helix, and proline is known to
have a low propensity for an -helix formation. Thus, such a
point mutation may lead to some destabilization of the protein
fold. L223P is not present in the healthy brother, is conserved
in human (Gene Bank accession number AY040777) and
mouse (NM175073), and was absent in 150 southern Italian
controls.
We emphasize the potential pitfall when selecting only pa-
tients with early onset for APTX screening. The identifica-
tion of patients with preserved knee jerks suggests also that
neuropathy is inconstant.4 To date, mutations have been
found only in the last three APTX exons. Thus, the screening
of such exons could be useful in sporadic or recessive patients
with cerebellar atrophy, after exclusion of FRDA.
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High Endogenous Cannabinoid Levels in the
Cerebrospinal Fluid of Untreated Parkinson’s
Disease Patients
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Endocannabinoids are a class of bioactive lipids responsible
for the activation of type 1 (CB1) and type 2 (CB2) can-
nabinoid receptors. A close functional interaction between
Fig. Superposition of the overall fold of the homology models
built for H166-F282 aprataxin and its L223P mutant with
3D-PSSM software.5 -Helices and -strands are represented in
gray and black, respectively. The alignment between H166-
F282 sequence and the template (protein kinase C inhibitor–1;
pdb code  1kpf) shows short deletions only in loop regions.
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